Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al
J Thromb Haemost
.
2022 Feb;20(2):542-543.
doi: 10.1111/jth.15619.
Authors
Andreas Greinacher
1
,
Florian Langer
2
,
Mike Makris
3
,
Menaka Pai
4
,
Sue Pavord
5
,
Huyen Tran
6
,
Theodore E Warkentin
4
Affiliations
1
Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.
2
Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany.
3
Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
4
Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
5
Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
6
Australian Centre for Blood Diseases, Clinical Haematology Department, Monash University, Melbourne, Victoria, Australia.
PMID:
35060304
DOI:
10.1111/jth.15619
No abstract available
Publication types
Letter
Comment
MeSH terms
Autoimmunity
Humans
Purpura, Thrombocytopenic, Idiopathic*
Thrombocytopenia* / chemically induced
Thrombocytopenia* / diagnosis
Thrombocytopenia* / therapy
Thrombosis*
Vaccines*
Substances
Vaccines